New Companies
Filter News
Found 4,212 articles
-
Rapport Therapeutics tops this year’s list with $250 million in Series A and B financing in just six months. -
Greg Slabodkin, Heather McKenzie and Tyler Patchen discuss BioSpace's tenth annual NextGen list of the hottest new life sciences companies. -
OneOne Biosciences Partners with Ginkgo Bioworks to Advance its Platform and Nitrogen Fixation Microbial Product
12/20/2023
OneOne Biosciences, a French startup building a comprehensive suite of agricultural microbial solutions for farmers, and Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new partnership.
-
Five years ago, Kyowa Kirin set out to expand its North America operations, adding new employees and capabilities at a rapid pace. The Human Resources team ensures employee input is central to managing that growth and nurturing a culture to support it
-
Novozymes and Chr. Hansen announce name of future combined company; Novonesis
12/13/2023
Novozymes and Chr. Hansen announced their future name ‘Novonesis’. The name reflects the beginning of an era of biosolutions where Novonesis will unleash the full potential of biological solutions and generate significant value for all stakeholders and society at large.
-
Introducing Portal Biotechnologies
12/12/2023
Portal Biotechnologies, Inc., a cell engineering platform company, announced its emergence from stealth.
-
Quotient Therapeutics, co-located in Cambridge, Mass. and Cambridge, U.K., will receive $50 million over two years from Flagship to study somatic genomics with an eye to finding new targets for gene therapies.
-
The new company, Mural Oncology, will continue registrational studies of its IL-2 cytokine in melanoma and ovarian cancer utilizing a $275 million cash runway expected to take them to the end of 2025. -
The UK-based nanomedicine biotech, previously known as SomaServe, has closed its Series A with some significant biopharma names attached. -
The biotech venture capital firm, led by former Andreessen Horowitz senior partner Kouki Harasaki, emerged from stealth on Wednesday focused on investing in companies with first-in-class or best-in-class therapies.
-
Here’s how expanding companies can benefit from executive-level strategic experience in key areas while staying lean and nimble.
-
Uniting thought leaders across the life sciences landscape, JLABS @ NYC rejoices in five years of catalyzing startups. -
Evident Vascular Announces Scientific Advisory Board and New Board Member
10/30/2023
Evident Vascular, Inc. announced today its Scientific Advisory Board and expansion of its Board of Directors.
-
The moment of coming out of stealth mode is ripe for biotechs to stumble. Here’s how to get it right. -
Tevogen Bio Introduces Tevogen.ai to Enhance Patient Accessibility and Accelerate Innovation Leveraging Artificial Intelligence
10/10/2023
Tevogen Bio Inc announces the inception of Tevogen.ai, a new initiative focused on harnessing the potential of artificial intelligence for the enhancement of drug discovery, development, manufacturing, distribution, and patient access.
-
The Alter Pharma Group is Becoming A.forall
9/27/2023
Milla Pharmaceutical Inc., a subsidiary of the Alter Pharma Group, is now becoming an A.forall company - The Alter Pharma Group, a group of generic and pharmacy sales companies, is rebranding all its brands and businesses into A.forall.
-
Accelerator Life Science Partners Launches Biotechnology Startup Company in Singapore with $16M in Series A Commitments
9/27/2023
Accelerator Life Science Partners announced the Series A financing of Automera, a new biotechnology company that focuses on the development of autophagy-targeting chimera small molecules.
-
CCM Biosciences Announces Launch of Protein Upregulation Business Unit
9/20/2023
CCM Biosciences announced its latest business unit — CCM Protein Upregulation — dedicated to advancing first-in-class drug leads for age-related conditions such as Alzheimer's, Parkinson's, and infertility as well as for genetically inherited diseases such as cystic fibrosis, using highly differentiated technology platforms for improving the enzymatic activity or expression level of critical proteins implicated in the pathogenesis of such disorders.
-
ALSA Ventures launches novel Gene Therapy portfolio company Axovia Therapeutics to treat Ciliopathies
9/19/2023
ALSA Ventures, a UK-based, therapeutics-focused venture capital fund, announces the acquisition of Axovia Therapeutics Inc and the launch of a new portfolio company Axovia Therapeutics Ltd.
-
Virpax Pharmaceuticals Announces the Formation of Novvae™ Pharmaceuticals
9/18/2023
Virpax ® Pharmaceuticals, Inc. today announced that it has formed a new wholly-owned subsidiary, Novvae™ Pharmaceuticals, Inc. (Novvae), which has been established to focus exclusively on advancing Virpax’s OTC pipeline.